# Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
Canonical URL: https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-to-present-new-preclinical-data-supporting-construct-design-of-tsha-102-for-rett-syndrome-at-the-asgct-2026-annual-meeting
Ticker: TSHA
Company: Taysha Gene Therapies
Source: Taysha Gene Therapies
Published: 2026-04-27 21:22 EST
Original Source URL: https://ir.tayshagtx.com
## Summary

In vitro data demonstrated self-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 (ssAAV9), supporting the ability to effectively deliver TSHA-102 to the CNS by lumbar IT administration MiniMeCP2 is functionally comparable to full-length

## Article Body
In vitro data demonstrated self-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 (ssAAV9), supporting the ability to effectively deliver TSHA-102 to the CNS by lumbar IT administration MiniMeCP2 is functionally comparable to full-length
## Recent Company News
- 2026-06-25 20:01 EST — [Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-multiple-presentations-highlighting-its-tsha-102-4055adda) — Source: Taysha Gene Therapies
- 2026-06-25 02:34 EST — [Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-pricing-of-public-offering-of-common-stock-and-p-2e78d875) — Source: Taysha Gene Therapies
- 2026-06-24 20:01 EST — [Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-proposed-public-offering-of-common-stock-and-pre-4e5395e4) — Source: Taysha Gene Therapies
- 2026-06-22 12:00 EST — [Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-completion-of-dosing-in-reveal-pivotal-trial-and-251737f9) — Source: Taysha Gene Therapies
- 2026-06-05 12:01 EST — [Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635--0dbdf043) — Source: Taysha Gene Therapies
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)